CLIP-II: The Cryopreserved vs. Liquid Platelets trial, a phase III multicentre, blinded, randomised controlled clinical non-inferiority trial of cryopreserved platelets verses conventional liquid-stored platelets for the management of surgical bleeding. This study is being conducted in collaboration with the Australian Red Cross Blood Service. The study will recruit participants, who are undergoing cardiac surgery and deemed to be of high risk for surgical bleeding, from approximately 12-14 Australian hospitals.
Goal: The aim of the study is to assess the efficacy, safety and cost effectiveness of cryopreserved platelets, compared to conventional liquid-stored platelets, for the management of surgical bleeding.
Rationale: Platelet transfusion is a life-saving component of the treatment of major bleeding. However, for logistic reasons and in order to use this scarce resource optimally, liquid-stored platelets are not stored in smaller hospitals, or in deployed military hospitals. Patients in these hospitals therefore currently have limited or no access to platelet transfusion. Cryopreservation of platelets is a promising technology that would allow smaller hospitals to provide platelet transfusions, reduce overall platelet wastage, and possibly produce better patient outcomes through more effective haemostasis.
Study Progress: The study has ethical approval and is scheduled to start at vanguard sites in late 2020.
Trial Registration: ClinicalTrials.gov ID: NCT03991481
Endorsement: The CLIP-II study is endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS-CTG), the ANZCA Clinical Trials Network, and the Australian and New Zealand Society of Cardiac and Thoracic Surgeons.
Funding: The CLIP-II Study is funded by a project grant from the National Health and Medical Research Council (NHMRC) of Australia.
Contact: For further information about this study, please contact the ANZIC-RC CLIP-II Project Manager, Belinda Howe by email.